Successful launch of CellaVision® DM1200 and a solid earnings trend
* Net sales increased by 12% to SEK 69.6 million (62.1), of which
the third quarter accounted for SEK 27.0 million (20.8).
* The operating profit for the period was SEK 7.3 million (6.3),
and for the third quarter SEK 5.5 million (3.6).
* Earnings per share for the period amounted to SEK 0.28 (0.25),
and for the third quarter SEK 0.22 (0.14).
* Cash and cash equivalents amounted to SEK 11.9 million (11.3) by
the end of the period.
* The new analyzer CellaVision® DM1200 became commercially
available in Europe and Canada and was successfully introduced on
the market. The first substantial order was taken in Europe.
CellaVision in summary
(MSEK) Q3 2009 Q3 2008 Jan-Sep 2009 Jan-Sep Full year
2008 2008
Net sales 27.0 20.8 69.6 62.1 100.4
Gross profit 20.1 16.6 51.0 42.4 63.5
Operating 5.5 3.6 7.3 6.3 13.4
result
Net result 5.4 3.4 6.8 6.0 13.1
Cash flow 2.6 -5.6 -7.7 -5.0 3.3
CEO's comment
"Our new product CellaVision DM1200 is now commercially available in
both Europe and Canada which will be beneficial for sales," says
Yvonne Mårtensson, CEO of CellaVision. "We got the first substantial
order from our distributor Sysmex Europe. The order comprised close
to twenty analyzers, which indicates that adapting our product to the
needs of medium-sized hospitals was strategically correct."
"We show solid increase in terms of both revenue and results during
the third quarter despite the global financial crisis, and we
continue to show a strong gross margin."
"During the quarter our own sales organizations have taken orders
from important customers in the USA, Canada, Japan, as well as the
Nordic region, and we continue to work hard to strengthen our
position in each of those markets."
Yvonne Mårtensson
CEO CellaVision AB
For further information, please contact:
Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail:
yvonne.martensson@cellavision.com
Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail:
johan.wennerholm@cellavision.com
